Mindray fights back after fraud allegations hit share price
This article was originally published in Clinica
Executive Summary
Number-one Chinese patient monitoring and IVD firm Mindray Medical International has hit back after a report accused it of hoodwinking investors. The firm’s share price on the New York Stock Exchange dipped 11% to close at $35.61 on 12 December when Ottoman Bay Research first tweeted a link to its report, saying: “Our 103-page deck details why we believe Mindray is a fraud.”
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.